文献速递淋巴瘤

外周T细胞淋巴瘤患者血浆中检测到RHOA第2外显子多种突变

Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T-cell lymphoma.
PubMed 文献 · Blood Adv · 2020-01-01

对外周T细胞淋巴瘤(PTCL)患者血浆游离DNA(cfDNA)进行靶向测序,除已知的RHOA c.50G>T(p.Gly17Val)外,还检测到第2外显子新突变c.73A>G(p.Phe25Leu)和c.48A>T(p.Cys16*),并经Sanger测序确认;液滴数字PCR在血管免疫母细胞性T细胞淋巴瘤(AITL)和PTCL-NOS患者中检出上述突变,系列采样显示RHOA突变频率随治疗变化并与复发相关。

要点

  • PTCL患者血浆cfDNA中可检出RHOA第2外显子c.50G>T、c.73A>G和c.48A>T突变。
  • 液滴数字PCR显示AITL和PTCL-NOS中c.50G>T占63%(12/19)、c.73A>G占53%(10/19)、c.48A>T占37%(7/19)。
  • 单个RHOA等位基因可携带一个以上突变,提示存在突变单倍型,且突变频率随治疗变化并与复发相关。

核心结论

  • 对血浆cfDNA中的RHOA进行测序发现了新的突变和单倍型,这些发现的临床意义需在临床试验中探索,液体活检可能有助于指导PTCL的治疗决策。

研究设计与样本

  • 对PTCL患者血浆cfDNA进行靶向测序,并用Sanger测序确认所检出的突变。
  • 对一组AITL和PTCL-NOS患者采用液滴数字聚合酶链反应进行分析。
  • 对9例中的3例淋巴结组织进行测序,确认存在c.73A>G(p.Phe25Leu)。
  • 对个体患者进行系列采样,观察RHOA突变频率随治疗的变化。

主要发现

  • 在AITL和PTCL-NOS患者中,63%(12/19)检出c.50G>T(p.Gly17Val),53%(10/19)检出c.73A>G(p.Phe25Leu),37%(7/19)检出c.48A>T(p.Cys16*)。
  • 9例中3例淋巴结组织测序确认存在c.73A>G(p.Phe25Leu)。
  • 对个体患者测序reads的检查显示,单个RHOA等位基因可含有一个以上突变,提示存在RHOA突变单倍型。
  • 系列采样显示RHOA突变频率随治疗发生变化,并出现与复发相关的携带特定单倍型的克隆。

局限性

  • 这些发现的临床意义将需要在临床试验中探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The mutational landscape of peripheral T-cell lymphoma (PTCL) is being revealed through sequencing of lymph node samples, but there has been little work on the mutational load that is present in cell-free DNA (cfDNA) from plasma. We report targeted sequencing of cfDNA from PTCL patients to demonstrate c.50G>T (p.Gly17Val) in RHOA as previously described in angioimmunoblastic T-cell lymphoma (AITL) and a group of PTCL not otherwise specified (NOS) but also detect novel mutations at c.73A>G (p.Phe25Leu) and c.48A>T (p.Cys16*) of exon 2, which were confirmed by Sanger sequencing. In a group of AITL and PTCL-NOS analyzed by droplet digital polymerase chain reaction, 63% (12/19) showed c.50G>T (p.Gly17Val), 53% (10/19) c.73A>G (p.Phe25Leu), and 37% (7/19) c.48A>T (pCys16*). Sequencing of lymph node tissue in 3 out of 9 cases confirmed the presence of c.73A>G (p.Phe25Leu). Inspection of individual sequencing reads from individual patients showed that a single RHOA allele could contain >1 mutation, suggesting haplotypes of mutations at RHOA. Serial sampling showed changes to RHOA mutational frequency with treatment and the apparent occurrence of clones bearing specific haplotypes associated with relapse. Therefore, sequencing of RHOA from cfDNA has revealed new mutations and haplotypes. The clinical significance of these findings will need to be explored in clinical trials, but liquid biopsy might have potential for guiding treatment decisions in PTCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ottolini B, Nawaz N, Trethewey CS, et al. Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T-cell lymphoma. Blood Adv. 2020. PMID: 32484856. doi:10.1182/bloodadvances.2019001075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。